New Drug Application Withdrawn

Article

Bristol-Myers Squibb Pulls Vanlev

PRINCETON, NJ- Vanlev, the first antihypertensive drug to receive priority review by the Food and Drug Administration (FDA), has been withdrawn from the approval process. Bristol-Myers Squibb voluntarily pulled the application due to questions raised by the FDA regarding a potential side effect. Though infrequent, the possibility of angioedema, a localized swelling affecting the face, throat, lips, or tongue, has been cited in some cases. Vanlev was designed to inhibit simultaneously two key enzymes, the angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) that regulate blood pressure. Studies have shown that the drug significantly reduces both systolic and diastolic blood pressure. The company hopes to resubmit the application early next year after new data has been compiled.

Recent Videos
Mark Wiencek, PhD
Rebecca Crapanzano-Sigafoos, DrPH, CIC, AL-CIP, FAPIC
The CDC’s updated hospital respiratory reporting requirement has added new layers of responsibility for infection preventionists. Karen Jones, MPH, RN, CIC, FAPIC, clinical program manager at Wolters Kluwer, breaks down what it means and how IPs can adapt.
Studying for the CIC using a digital tablet and computer (Adobe Stock 335828989 by NIKCOA)
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Cheron Rojo, BS, FCS, CHL,  CER, CFER, CRCST
Matthias Tschoerner, Dr Sc
Standardizing Cleaning and Disinfection
Concept images of Far-UVC  (Adobe Stock 316993517 by hopenv)
Related Content